Found 1457 clinical trials
- 10 views
- 05 Nov, 2021
- 1 location
A Phase 2a, Double-blind, Randomized, Placebo-controlled, Proof of Concept Study of Vascular Endothelial Growth Factor (VEGF)-B Blockade with the Monoclonal Antibody CSL346 in Subjects with Diabetic Kidney Disease
This is a prospective, multicenter, randomized, double-blind, placebo-controlled, proof of concept study to investigate the efficacy, safety, tolerability, and pharmacokinetics (PK) of repeat doses of CSL346 in 100 subjects with DKD and albuminuria receiving standard of care treatment.
- 22 views
- 12 Oct, 2021
- 1 location
A Study of the Prevalence of Apolipoprotein L1 (APOL1) Alleles Among Individuals With Proteinuric Kidney Disease Who Are of Recent African Ancestry or Geographic Origin
A Study of the Prevalence of Apolipoprotein L1 (APOL1) Alleles Among Individuals With Proteinuric Kidney Disease
- 0 views
- 29 Jul, 2021
- 1 location
Kidney Disease in Type 2 Diabetics
Kidney Disease in Type 2 Diabetics
- 1358 views
- 25 Mar, 2021
- 1 location
RENAL AID: Repository of Novel Analytes Leading to Autoimmune, Inflammatory, and Diabetic Nephropathies
RENAL AID: Repository of Novel Analytes Leading to Autoimmune, Inflammatory, and Diabetic Nephropathies
- 218 views
- 25 Mar, 2021
- 1 location
A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven PhaseIII study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease insubjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease
progression of kidney disease insubjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease
- 177 views
- 23 Nov, 2020
- 1 location
BAY-94-8862/16244 - A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease
standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease
- 1058 views
- 25 Mar, 2021
- 1 location
C0221002 FSGS
The purpose of this Phase 2 adaptive study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of PF-06730512 following multiple intravenous infusion in adult subjects with FSGS.
- 95 views
- 11 May, 2022
- 13 locations
AKB-6548-CI-0014 PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT - CORRECTION AND AKB-6548-CI-0015 PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT- CONVERSION
CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT - CORRECTION AND AKB-6548-CI-0015 PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE
- 374 views
- 25 Mar, 2021
- 1 location
AKB-6548-CI-0014 PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT - CORRECTION) AND AKB-6548-CI-0015 PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT- CONVERSION
CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT - CORRECTION) AND AKB-6548-CI-0015 PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE
- 270 views
- 25 Mar, 2021
- 1 location